Physician profile
Ian Stein
NPI 1710932520
$10,574.62
in general payments reported to CMS, 2019-2025
48 companies · $765 in 2025
The $765 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,671 · 2020: $1,799 · 2021: $2,142 · 2022: $2,415 · 2023: $444 · 2024: $339 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.68 |
| Education | $232.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,338.71 | 2021-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $954.77 | 2019-2022 | |
| Biogen, INC. | $794.17 | 2019-2023 | Vumerity |
| Eisai INC. | $628.24 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $471.33 | 2019-2022 | |
| Harmony Biosciences LLC | $447.84 | 2021-2025 | |
| Si-Bone, INC. | $419.66 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $400.16 | 2019-2021 | |
| Lundbeck LLC | $371.41 | 2019-2023 | Vyepti |
| Genzyme Corporation | $367.66 | 2019-2021 | |
| Amgen INC. | $327.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $264.28 | 2019-2021 | |
| Csl Behring | $252.37 | 2020-2025 | Hizentra, Kcentra |
| Ucb, INC. | $249.74 | 2019-2021 | |
| Akcea Therapeutics, INC. | $246.34 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.